Factor VIII and IX deficiencies related to acquired inhibitors in a patient with chronic hepatitis C virus infection receiving treatment with pegylated interferon plus ribavirin

References

• Holme PA, Brosstad F, Tjønnfjord GE Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies. Haemophilia 2005;11:510–5.
   PubMed Web of Science ®Google Scholar
• Kempton CL White GC 2nd. How we treat a hemophilia A patient with a factor VIII inhibitor. Blood 2009;113:11–7.
   PubMed Web of Science ®Google Scholar
• Franchini M, Targher G, Montagnana M, Lippi G Laboratory, clinical and therapeutic aspects of acquired hemophilia A. Clin Chim Acta 2008;395:14–8.
   PubMed Web of Science ®Google Scholar
• Green D, Lechner K A survey of 215 non‐hemophilic patients with inhibitors to FVIII. Thromb Haemost 1981;45:200–3.
   PubMed Web of Science ®Google Scholar
• Franchini M, Gandini G, Di Paolantonio T, Mariani G Acquired hemophilia A: a concise review. Am J Hematol 2005;80:55–63.
   PubMed Web of Science ®Google Scholar
• Hay CR, Negrier C, Ludlam CA The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study. Thromb Haemost 1997;78:1463–7.
   PubMed Web of Science ®Google Scholar
• Shima M Characterization of factor VIII inhibitors. Int J Hematol 2006;83:109–18.
   PubMed Web of Science ®Google Scholar
• Hay CR, Brown S, Collins PW, Keeling DM, Liesner R. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol 2006;133:591–605.
   PubMed Web of Science ®Google Scholar
• Cohen AJ, Kessler CM Acquired inhibitors. Baillieres Clin Haematol 1996;9:331–54.
   PubMed Web of Science ®Google Scholar
• Okuse C, Yotsuyanagi H, Koike K Hepatitis C as a systemic disease: virus and host immunologic responses underlie hepatic and extrahepatic manifestations. J Gastroenterol 2007;42:857–65.
   PubMed Web of Science ®Google Scholar
• Craxì A, Laffi G, Zignego AL Hepatitis C virus (HCV) infection: a systemic disease. Mol Aspects Med 2008;29:85–95.
   PubMed Web of Science ®Google Scholar
• Castenskiold EC, Colvin BT, Kelsey SM Acquired factor VIII inhibitor associated with chronic interferon‐alpha therapy in a patient with haemophilia A. Br J Haematol 1994;87:434.
   PubMed Web of Science ®Google Scholar
• Schreiber ZA, Bräu N Acquired factor VIII inhibitor in patients with hepatitis C virus infection and the role of interferon‐alpha: a case report. Am J Hematol 2005;80:295–8.
   PubMed Web of Science ®Google Scholar
• Dentale N, Fulgaro C, Guerra L, Fasulo G, Mazzetti M, Fabbri C Acquisition of factor VIII inhibitor after acute hepatitis C virus infection. Blood 1997;90:3233–4.
   PubMed Web of Science ®Google Scholar
• Sugishita K, Nagase H, Takahashi T, Takenaka K, Shiratori Y, Omata M Acquired factor VIII inhibitor in a non‐hemophilic patient with chronic hepatitis C viral infection. Intern Med 1999;38:283–6.
   PubMed Web of Science ®Google Scholar
• De Almeida AJ, Campos‐de‐Magalhães M, Brandaã‐Mello CE, de Oliveira RV, do Espirito‐Santo MP, Yoshida CF, et al.. Detection of hepatitis C virus in platelets: evaluating its relationship to antiviral therapy outcome. Hepatogastroenterology 2009;56:429–36.
   PubMed Web of Science ®Google Scholar
• Bouchardeau F, Cantaloube JF, Chevaliez S, Portal C, Razer A, Lefrère JJ, et al.. Improvement of hepatitis C virus (HCV) genotype determination with the new version of the INNO‐LiPA HCV assay. J Clin Microbiol 2007;45:1140–5.
   PubMed Web of Science ®Google Scholar
• Bedossa P, Poynard T An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289–93.
   PubMed Web of Science ®Google Scholar
• Kasper CK, Aledort L, Aronson D, Counts R, Edson JR, van Eys J, et al.. Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975;34:612.
   PubMedGoogle Scholar
• Darby SC, Keeling DM, Spooner RJ, Wan Kan S, Giangrande PL, Collins PW, et al.. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977–99. J Thromb Haemost 2004;2:1047–54.
   PubMed Web of Science ®Google Scholar
• Joyce MA, Tyrrell DL The cell biology of hepatitis C virus. Microbes Infect 2010;12:263–71.
   PubMed Web of Science ®Google Scholar
• Reding MT Immunological aspects of inhibitor development. Haemophilia 2006;12:30–36.
   PubMed Web of Science ®Google Scholar
• Lacroix‐Desmazes S, Navarrete AM, André S, Bayry J, Kaveri SV, Dasgupta S Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A. Blood 2008;112:240–9.
   PubMed Web of Science ®Google Scholar
• DiMichele DM Inhibitor treatment in haemophilias A and B: inhibitor diagnosis. Haemophilia 2006;12:37–41.
   PubMed Web of Science ®Google Scholar
• Ma AD, Carrizosa D Acquired factor VIII inhibitors: pathophysiology and treatment. Hematology Am Soc Hematol Educ Program 2006, 432–7.
   PubMedGoogle Scholar
• Asselah T, Benhamou Y, Marcellin P Protease and polymerase inhibitors for the treatment of hepatitis C. Liver Int 2009;29:57–67.
   PubMed Web of Science ®Google Scholar
• Flisiak R, Parfieniuk A Investigational drugs for hepatitis C. Expert Opin Investig Drugs 2010;19:63–75.
   PubMed Web of Science ®Google Scholar
• Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997;26:112S–21S.
   PubMed Web of Science ®Google Scholar
• Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology 2003;124:1711–9.
   PubMed Web of Science ®Google Scholar
• Papo T Interféron alpha et auto‐immunité. Rev Med Interne 2002;23:501s–10s.
   PubMed Web of Science ®Google Scholar
• Pellicano R, Smedile A, Peyre S, Astegiano M, Saracco G, Bonardi R, et al.. Autoimmune manifestations during interferon therapy in patients with chronic hepatitis C: the hepatologist’s view. Minerva Gastroenterol Dietol 2005;51:55–61.
   PubMedGoogle Scholar
• Modi AA, Liang TJ Hepatitis C: a clinical review. Oral Dis 2008;14:10–4.
   PubMed Web of Science ®Google Scholar
• Magrin S, Craxì A, Fabiano C, Simonetti RG, Fiorentino G, Marino L, et al.. Hepatitis C viremia in chronic liver disease: relationship to interferon‐alpha or corticosteroid treatment. Hepatology 1994;19:273–9.
   PubMed Web of Science ®Google Scholar
• Hedner U Mechanism of action of recombinant activated factor VII: an update. Semin Hematol 2005;43:S105–7.
   Web of Science ®Google Scholar
• Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. Thromb Haemost 1997;77:1113–9.
   PubMed Web of Science ®Google Scholar